News | June 16, 2008

GE to Distribute Gamma Medica-Ideas' Pre-Clinical Imaging

June 17, 2008 - Gamma Medica-Ideas and GE Healthcare signed an agreement that GE Healthcare will be the exclusive distributor of Gamma Medica-Ideas' preclinical imaging products effective July 1, 2008, as announced at the 55th annual meeting of the Society of Nuclear Medicine.

Pre-Clinical imaging plays a key role in new pharmaceutical therapeutic development by allowing researchers to visualize the structure, function and response of laboratory animals in vivo.

The agreement complements GE Healthcare's portfolio of pre-clinical products, and grants researchers greater access to GM-I's fully-digital trimodality Positron Emission Tomography (PET); Single Photon Emission Computed Tomography (SPECT) and Computed Tomography (CT) scanners.

"This agreement is an opportunity for customers to gain greater access to our hybrid scanners by leveraging the extensive footprint of GE Healthcare,"? said Bradley Patt, Ph.D., president and CEO of GM-I. "We were first to market a trimodal preclinical scanner, and our all-digital technology provides improved spatial resolution, while enabling researchers to share images easily-bringing digital pathology to the pre-clinical arena."

Gamma Medica-Ideas have installed more than 50 multi-modality systems on four continents since 2002. The company's first-to-market all-digital technologies have made it a leader in pre-clinical imaging systems.

"GE Healthcare is excited to be working with Gamma Medica-Ideas," said Eugene Saragnese, vice president and general manager, molecular imaging and CT, GE Healthcare. "This agreement underscores our deep commitment to the molecular imaging and preclinical markets. Many innovations in clinical imaging get their start in the pre-clinical devices, and we continue to look to that space as a showcase for what's possible for the future of human PET, SPECT and CT imaging."

GE Healthcare already offers dual-modality PET/CT, CZT based SPECT/CT and dedicated in-vivo and specimen preclinical CT scanners. The agreement with GM-I brings scalable and upgradeable tri-modal (PET/SPECT/CT) systems under the GE umbrella.

"Researchers across the globe will reap the benefits of the combined multi-modality pre-clinical portfolio of GE Healthcare and Gamma Medica-Ideas accelerating studies to investigate disease biology and develop new drugs,"? said James Mitchell, general manager, molecular imaging technologies, GE Healthcare. "This agreement makes for a one-stop-shop for pre-clinical imaging devices."

For more information: www.gehealthcare.com

Related Content

advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...
brain SPECT imaging, dementia, depression, Daniel G. Amen

Representative brain SPECT scans in a patient with Alzheimer's dementia showing substantially reduced brain blood flow in the temporal and parietal lobes compared to a person with depression with mild decreased frontal lobe blood flow. Image courtesy of Amen Clinics.

News | SPECT Imaging | February 22, 2017
February 22, 2017 — Does a patient have depression or a cognitive disorder (CD) such as Alzheimer's disease or both?
News | Nuclear Imaging | December 12, 2016
Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected...
xSPECT Quant technology, SPECT/CT, Symbia Intevo, Siemens Healthineers, RSNA 2016
News | SPECT Imaging | December 06, 2016
December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
News | Radiopharmaceuticals and Tracers | September 06, 2016
Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging | July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
Overlay Init